Items

• Kliničke vodilje za tretman HIV-a i AIDS-a u Bosni i Hercegovini (2016)

  A. Verhaz, S. Adžić, Z. Čardaklija, S. Hadžialjević, V. Hadžiosmanović, Z. Kezić, T. Kovačević, J. Medar-Petrović, D. Milaković, A. Novo, S. Skočibušić, S. Stojisavljević, S. Šabović, Kliničke vodilje za tretman HIV-a i AIDS-a u Bosni i Hercegovini, pp. 86 - 100, Udruženje "Partnerstvo za zdravlje", Sarajevo, 2016

• Liječenje oboljelih sa koinfekcijama: Hepatitis B i C i HIV.; Tuberkuloza i HIV (2016)

  A. Verhaz, Z. Čardaklija, S. Adžić, S. Hadžialjević, V. Hadžiosmanović, Z. Kezić, T. Kovačević, J. Medar-Petrović, D. Milaković, A. Novo, S. Skočibušić, S. Stojisavljević, S. Šabović, Liječenje oboljelih sa koinfekcijama: Hepatitis B i C i HIV.; Tuberkuloza i HIV, Kliničke vodilje za tretman HIV-a i AIDS-a u Bosni i Hercegovini, pp. 121 - 140, udruženje "Partnerstvo za zdravlje", Sarajevo, 2016

• Doziranje vankomicina i gentamicina kod kritično oboljelih u KC Banja Luka (2014)

  T. Kovačević, P. Kovačević, S. Avram, D. Milaković, N. Špirić, Doziranje vankomicina i gentamicina kod kritično oboljelih u KC Banja Luka, ČASOPIS UDRUŽENJA PULMOLOGA REPUBLIKE SRPSKE, pp. 75 - 81, 2014

• Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients (2016)

  T. Kovačević, P. Kovačević, A. Sanja, D. Milaković, N. Špirić, Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients, Journal of Basic and Clinical Pharmacy, Vol. 7, No. 3, pp. 65 - 69, 2016

• Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfi, C. Hee Suh, S. Cheol Shim, S. Joon Lee, S. Young Lee, S. Hwan Kim, D. Hyun Yoo, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, US National Library of Medicine National Institutes of Health, pp. 100 - 101, Sep, 2016

• Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial (2018-08)

  W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. El-Khouri, F. Irazoque-Palazuelos, F. Molina, P. Shesternya, P. Miranda, F. Medina-Rodriguez, Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial, Pubmed, pp. 934 - 943, Aug, 2018

• Variation of the Radiochemical Purity of 99mTc-Sestamibi Reconstituted by Different Generator's Eluates. (2014)

  A. Stanković, Z. Rajkovača, D. Milaković, G. Vuleta, Variation of the Radiochemical Purity of 99mTc-Sestamibi Reconstituted by Different Generator's Eluates., Eur J Nucl Med Mol Imaging, 2014

• 99mTc-colloidal rhenium sulphide influence of different generators eluates on fluctuations in radiochemical purity (2015)

  A. Stanković, D. Milaković, Z. Rajkovača, 99mTc-colloidal rhenium sulphide influence of different generators eluates on fluctuations in radiochemical purity, World Journal of Nuclear Medicine, 2015

• 99mTc Colloid Rhenium Sulphide: Influence of different generator’s eluates on fluctuations in radiochemical purity, (2015)

  A. Stanković, Z. Rajkovača, D. Milaković, 99mTc Colloid Rhenium Sulphide: Influence of different generator’s eluates on fluctuations in radiochemical purity,, World J Nucl Med, pp. 100 - 101, 2015